Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding
Avainsanat
Abstrakti
Kuvaus
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death.A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients.Dipeptidyl peptidase 4 (DPP4) is an exopeptidase expressed on the surface of diverse cells, cleaving off amino-terminal dipeptides with either L-proline, L-alanine or serine at the penultimate position. As a cell surface protein, it participates in immune regulation, signal transduction and apoptosis. DPP4 also circulates as a soluble form in the plasma. Soluble DPP4 came from either membrane type clearance or secreted by cells like endothelial cells, with enzymatic activity. Plasma DPP4 activity (DPP4a) are elevated in several diseases, including type 2 diabetes, obesity, atherosclerosis and osteoporosis. Basic studies have showed that DPP4 inhibition leads improved survival and heart function after cardiac ischemia-reperfusion (I/R) injury, and this is partly due to activation of AKT (pAKT), pGSK3 and ANP pathways. Also inhibition of DPP4 can alleviate atherosclerosis and heart failure. Accordingly, one could hypothesize that high DPP4a may worsen myocardial I/R injury, causing poorer cardiovascular outcomes. However, no study has evaluated whether DPP4a is associated with adverse clinical outcomes in STEMI patients.
Päivämäärät
Viimeksi vahvistettu: | 06/30/2016 |
Ensimmäinen lähetys: | 07/23/2016 |
Arvioitu ilmoittautuminen lähetetty: | 07/25/2016 |
Ensimmäinen lähetetty: | 07/28/2016 |
Viimeisin päivitys lähetetty: | 07/25/2016 |
Viimeisin päivitys lähetetty: | 07/28/2016 |
Todellinen opintojen alkamispäivä: | 12/31/2013 |
Arvioitu ensisijainen valmistumispäivä: | 09/30/2015 |
Ehto tai tauti
Vaihe
Varren ryhmät
Varsi | Interventio / hoito |
---|---|
Quartile 1 Quartile 1 of plasma DPP4 activity | |
Quartile 2 Quartile 2 of plasma DPP4 activity | |
Quartile 3 Quartile 3 of plasma DPP4 activity | |
Quartile 4 Quartile 4 of plasma DPP4 activity |
Kelpoisuusehdot
Sukupuolet, jotka ovat kelpoisia tutkimukseen | All |
Näytteenottomenetelmä | Non-Probability Sample |
Hyväksyy terveelliset vapaaehtoiset | Joo |
Kriteeri | Inclusion Criteria: - a diagnosis of STEMI and needed PCI Exclusion Criteria: - patients with cancer - patients who used DPP4 inhibitor - patients who used GLP1 analogue |
Tulokset
Ensisijaiset tulosmittaukset
1. a change in the prevalence of no-reflow [immediately after PCI]
Toissijaiset tulosmittaukset
1. in-hospital major adverse cardiac or cerebrovascular events [up to 2 week after PCI (until discharge)]
2. in-hospital complications [up to 2 week after PCI (until discharge)]
3. in-hospital major bleeding [up to 2 week after PCI (until discharge)]